CUREVAC NV (5CV.DE) Stock Fundamental Analysis
FRA:5CV - Deutsche Boerse Ag - NL0015436031 - Common Stock - Currency: EUR
5CV gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 73 industry peers in the Biotechnology industry. 5CV has an excellent financial health rating, but there are some minor concerns on its profitability. 5CV is not priced too expensively while it is growing strongly. Keep and eye on this one! With these ratings, 5CV could be worth investigating further for growth investing!.
1. Profitability
1.1 Basic Checks
5CV had positive earnings in the past year.
In the past year 5CV had a positive cash flow from operations.
In the past 5 years 5CV always reported negative net income.
In the past 5 years 5CV reported 4 times negative operating cash flow.
1.2 Ratios
5CV has a Return On Assets of 12.68%. This is amongst the best in the industry. 5CV outperforms 95.83% of its industry peers.
With an excellent Return On Equity value of 14.94%, 5CV belongs to the best of the industry, outperforming 90.28% of the companies in the same industry.
5CV has a Return On Invested Capital of 12.25%. This is amongst the best in the industry. 5CV outperforms 90.28% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 12.68% | ||
| ROE | 14.94% | ||
| ROIC | 12.25% |
ROA(3y)-32.5%
ROA(5y)-36.5%
ROE(3y)-52.27%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
5CV's Profit Margin of 19.93% is amongst the best of the industry. 5CV outperforms 90.28% of its industry peers.
5CV's Operating Margin of 24.34% is amongst the best of the industry. 5CV outperforms 87.50% of its industry peers.
5CV has a Gross Margin of 70.93%. This is in the better half of the industry: 5CV outperforms 72.22% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 24.34% | ||
| PM (TTM) | 19.93% | ||
| GM | 70.93% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), 5CV is creating some value.
Compared to 1 year ago, 5CV has more shares outstanding
Compared to 5 years ago, 5CV has more shares outstanding
5CV has a worse debt/assets ratio than last year.
2.2 Solvency
5CV has an Altman-Z score of 5.95. This indicates that 5CV is financially healthy and has little risk of bankruptcy at the moment.
5CV's Altman-Z score of 5.95 is amongst the best of the industry. 5CV outperforms 90.28% of its industry peers.
The Debt to FCF ratio of 5CV is 0.42, which is an excellent value as it means it would take 5CV, only 0.42 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of 5CV (0.42) is better than 97.22% of its industry peers.
5CV has a Debt/Equity ratio of 0.05. This is a healthy value indicating a solid balance between debt and equity.
With a decent Debt to Equity ratio value of 0.05, 5CV is doing good in the industry, outperforming 75.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | 0.42 | ||
| Altman-Z | 5.95 |
ROIC/WACC1.74
WACC7.03%
2.3 Liquidity
5CV has a Current Ratio of 6.20. This indicates that 5CV is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 6.20, 5CV belongs to the top of the industry, outperforming 86.11% of the companies in the same industry.
5CV has a Quick Ratio of 6.19. This indicates that 5CV is financially healthy and has no problem in meeting its short term obligations.
5CV has a better Quick ratio (6.19) than 86.11% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.2 | ||
| Quick Ratio | 6.19 |
3. Growth
3.1 Past
5CV shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 134.53%, which is quite impressive.
5CV shows a strong growth in Revenue. In the last year, the Revenue has grown by 1166.88%.
Measured over the past years, 5CV shows a very strong growth in Revenue. The Revenue has been growing by 33.04% on average per year.
EPS 1Y (TTM)134.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%781.82%
Revenue 1Y (TTM)1166.88%
Revenue growth 3Y3.21%
Revenue growth 5Y33.04%
Sales Q2Q%2896.43%
3.2 Future
The Earnings Per Share is expected to grow by 9.02% on average over the next years. This is quite good.
The Revenue is expected to grow by 28.92% on average over the next years. This is a very strong growth
EPS Next Y164.54%
EPS Next 2Y25.04%
EPS Next 3Y20.69%
EPS Next 5Y9.02%
Revenue Next Year700.96%
Revenue Next 2Y7.81%
Revenue Next 3Y24.58%
Revenue Next 5Y28.92%
3.3 Evolution
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 5.96, the valuation of 5CV can be described as very cheap.
Based on the Price/Earnings ratio, 5CV is valued cheaper than 100.00% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 29.35. 5CV is valued rather cheaply when compared to this.
The Forward Price/Earnings Ratio is negative for 5CV. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.96 | ||
| Fwd PE | N/A |
4.2 Price Multiples
5CV's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. 5CV is cheaper than 97.22% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of 5CV indicates a rather cheap valuation: 5CV is cheaper than 97.22% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 6.79 | ||
| EV/EBITDA | 0.8 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as 5CV's earnings are expected to grow with 20.69% in the coming years.
PEG (NY)0.04
PEG (5Y)N/A
EPS Next 2Y25.04%
EPS Next 3Y20.69%
5. Dividend
5.1 Amount
5CV does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
FRA:5CV (3/7/2025, 7:00:00 PM)
2.86
-0.07 (-2.52%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners18.11%
Inst Owner ChangeN/A
Ins Owners0.18%
Ins Owner ChangeN/A
Market Cap641.61M
Analysts78.46
Price Target7.48 (161.54%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)71.53%
Min EPS beat(2)-18.39%
Max EPS beat(2)161.44%
EPS beat(4)1
Avg EPS beat(4)0.77%
Min EPS beat(4)-106.68%
Max EPS beat(4)161.44%
EPS beat(8)3
Avg EPS beat(8)-10.4%
EPS beat(12)6
Avg EPS beat(12)7.56%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)263.4%
Min Revenue beat(2)160.16%
Max Revenue beat(2)366.65%
Revenue beat(4)3
Avg Revenue beat(4)123.3%
Min Revenue beat(4)-34.43%
Max Revenue beat(4)366.65%
Revenue beat(8)3
Avg Revenue beat(8)45.65%
Revenue beat(12)6
Avg Revenue beat(12)67.41%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-1.04%
PT rev (3m)-1.75%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)67.16%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)58.32%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.96 | ||
| Fwd PE | N/A | ||
| P/S | 1.18 | ||
| P/FCF | 6.79 | ||
| P/OCF | 5.14 | ||
| P/B | 0.89 | ||
| P/tB | 0.92 | ||
| EV/EBITDA | 0.8 |
EPS(TTM)0.48
EY16.78%
EPS(NY)-0.52
Fwd EYN/A
FCF(TTM)0.42
FCFY14.73%
OCF(TTM)0.56
OCFY19.45%
SpS2.42
BVpS3.23
TBVpS3.11
PEG (NY)0.04
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 12.68% | ||
| ROE | 14.94% | ||
| ROCE | 17.4% | ||
| ROIC | 12.25% | ||
| ROICexc | 45.42% | ||
| ROICexgc | 52.09% | ||
| OM | 24.34% | ||
| PM (TTM) | 19.93% | ||
| GM | 70.93% | ||
| FCFM | 17.4% |
ROA(3y)-32.5%
ROA(5y)-36.5%
ROE(3y)-52.27%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score9
Asset Turnover0.64
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | 0.42 | ||
| Debt/EBITDA | 0.23 | ||
| Cap/Depr | 147.78% | ||
| Cap/Sales | 5.57% | ||
| Interest Coverage | 65.13 | ||
| Cash Conversion | 81.73% | ||
| Profit Quality | 87.29% | ||
| Current Ratio | 6.2 | ||
| Quick Ratio | 6.19 | ||
| Altman-Z | 5.95 |
F-Score9
WACC7.03%
ROIC/WACC1.74
Cap/Depr(3y)481.31%
Cap/Depr(5y)411.27%
Cap/Sales(3y)121.71%
Cap/Sales(5y)106.44%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)134.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%781.82%
EPS Next Y164.54%
EPS Next 2Y25.04%
EPS Next 3Y20.69%
EPS Next 5Y9.02%
Revenue 1Y (TTM)1166.88%
Revenue growth 3Y3.21%
Revenue growth 5Y33.04%
Sales Q2Q%2896.43%
Revenue Next Year700.96%
Revenue Next 2Y7.81%
Revenue Next 3Y24.58%
Revenue Next 5Y28.92%
EBIT growth 1Y142.75%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year201.38%
EBIT Next 3Y18.73%
EBIT Next 5Y24.53%
FCF growth 1Y117.93%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y129.71%
OCF growth 3YN/A
OCF growth 5YN/A